Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02628405

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:26:25.062655+00:00

Published At

2024-07-01T00:00:00+00:00

Record Updated At

2024-07-01

Results Posted At

2024-07-01

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Transformed Non-Hodgkin Lymphoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2024-07-01"

protocolSection.identificationModule.nctId

"NCT02628405"

protocolSection.identificationModule.officialTitle

"Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2024-07-01"

Study condition terms

• Recurrent B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Transformed Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Transformed Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.